Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHEN211 for Mild to Moderate COVID-19
NCT06288893Phase 2Not yet recruiting
- Sponsor
- JKT Biopharma Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHEN211 in coronavirus disease 2019 (COVID-19), sponsored by JKT Biopharma Co., Ltd.. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
SHEN211
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06288893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06288893.